Compare
Aytu Biopharma, Inc vs Nektar Therapeutics vs Nuvation Bio Inc. vs Ocular Therapeutix, Inc
| Latest fiscal year | Aytu Biopharma, Inc AYTU | Nektar Therapeutics NKTR | Nuvation Bio Inc. NUVB | Ocular Therapeutix, Inc OCUL |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $57.57M | $55.23M | $62.90M | $51.95M |
| Revenue growth (YoY) | -13.3% | -43.9% | +699.0% | -18.5% |
| Gross margin | 64.0% | n/a | n/a | 87.3% (computed) |
| Operating margin | -14.4% | -253.7% | -338.7% | -519.8% |
| Net margin | -24.8% | -297.1% | -325.3% | -511.9% |
| Net income | -$14.25M | -$164.08M | -$204.63M | -$265.94M |
| EPS (Diluted) | n/a | -$9.73 | -$0.60 | -$1.42 |
| Operating cash flow | $3.28M | -$208.51M | -$173.43M | -$204.88M |
| Free cash flow | $3.25M | -$208.68M | n/a | -$216.89M |
| Cash & equivalents | $26.31M | $15.12M | $164.09M | $737.06M |
| Total assets | $105.01M | $280.41M | $594.82M | $808.06M |
| Total liabilities | n/a | $190.57M | $289.11M | $153.75M |
| Shareholders' equity | $35.27M | $89.83M | $305.72M | $654.31M |
| Return on year-end equity | -40.4% | -182.6% | -66.9% | -40.6% |
| Shares outstanding | 10.73M | 20.38M | 337.84M | 215.93M |
Revenue, most recent five fiscal years
| Fiscal year | Aytu Biopharma, Inc | Nektar Therapeutics | Nuvation Bio Inc. | Ocular Therapeutix, Inc |
|---|---|---|---|---|
| Latest | $57.57M Ended 2026-06-30 | $55.23M Ended 2025-12-31 | $62.90M Ended 2025-12-31 | $51.95M Ended 2025-12-31 |
| 1 year earlier | $66.38M Ended 2025-06-30 | $98.43M Ended 2024-12-31 | $7.87M Ended 2024-12-31 | $63.72M Ended 2024-12-31 |
| 2 years earlier | $65.18M Ended 2024-06-30 | $90.12M Ended 2023-12-31 | $0 Ended 2023-12-31 | $58.44M Ended 2023-12-31 |
| 3 years earlier | $107.40M Ended 2023-06-30 | $92.06M Ended 2022-12-31 | n/a | $51.49M Ended 2022-12-31 |
| 4 years earlier | $96.67M Ended 2022-06-30 | $101.91M Ended 2021-12-31 | n/a | $43.52M Ended 2021-12-31 |